Lyrica

Lyrica is the brand name for (pregabalin) which is its active ingredient. It is used to treat Fibromyalgia, diabetic nerve pain, pain after shingles, spinal cord injure nerve pain, and partial onset seizures in adults (an add-on treatment) with epilepsy.

Side Effects
More commonly reported ones are:

More commonly reported ones in children are:

Less commonly reported ones are:

Generic legal battle

 * Mar 2012, Pfizer blocked Israel-based Teva Pharmaceutical Industries and other manufacturers from selling generic versions of Lyrica.


 * Jul 2012, the U.S. Food and Drug Administration (FDA) approved a generic version of Lyrica. Pregabalin, the active ingredient, is the generic name. Two weeks after being approved by the FDA marketing was blocked.


 * 2014, Pfizer Inc., the maker of Lyrica, successfully blocked the marketing of Pregabalin generics until December of 2018 arguing that the generics should not be marketed and made available until after their patent ran out. Warner-Lamber, (a subsidieary of Pfizer), "still holds a “second medical use” patent for the use of pregabalin in the treatment of peripheral and central neuropathic pain, which expires in July 2017. A second medical use patent is one that relates to a new medical use for a known compound."